Neuromyelitis Optica Spectrum Disorder: Reducing Relapse Through Early Intervention

Author(s)/Faculty: Michael S. Lee, MD; Prem S. Subramanian, MD, PhD; Brian G. Weinshenker, MD, FRCP(C), FAAN
Release Date: 1/25/2022Expiration Date: 1/24/2023
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 1.25
Content Type: LectureProvider:
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune disease characterized by inflammation in the optic nerve and spinal cord. Diagnosing NMOSD is challenging, but diagnostic criteria—based on the presence of core clinical characteristics, aquaporin-4 antibody status, and magnetic resonance imaging—have been developed that allow for a differential diagnosis from other inflammatory disorders of the central nervous system. Treatment options for NMOSD have been historically limited, until recently—when the US Food and Drug Administration approved several novel therapies for the treatment and prevention of NMOSD attacks. Further therapies are currently under clinical review for the same indication. These approved and emerging therapies are changing the treatment paradigm for NMOSD, providing enhanced clinical outcomes for these patients with the goal of reducing relapse through early intervention. Within this case-based program, experts in the field will utilize didactic presentations and a panel discussion to summarize evidence-based diagnostic criteria and best practices that assist in the differential diagnosis of NMOSD, as well as differentiate current NMOSD therapeutics based on their mechanisms of action, efficacy, safety, and administration.